Lipidor AB (OSTO:LIPI) Change In Receivables : kr1.78 Mil (TTM As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Lipidor AB Change In Receivables?

Lipidor AB's change in receivables for the quarter that ended in Jun. 2024 was kr-0.15 Mil. It means Lipidor AB's Accounts Receivable increased by kr0.15 Mil from Mar. 2024 to Jun. 2024 .

Lipidor AB's change in receivables for the fiscal year that ended in Dec. 2023 was kr0.93 Mil. It means Lipidor AB's Accounts Receivable declined by kr0.93 Mil from Dec. 2022 to Dec. 2023 .

Lipidor AB's Accounts Receivable for the quarter that ended in Jun. 2024 was kr0.47 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lipidor AB's liquidation value for the three months ended in Jun. 2024 was kr15.13 Mil.

Lipidor AB Change In Receivables Historical Data

The historical data trend for Lipidor AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipidor AB Change In Receivables Chart

Lipidor AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

1.20

0.14

-1.48

0.13

0.93

Lipidor AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Change In Receivables	Get a 7-Day Free Trial															-1.40	1.59	0.39	-0.05	-0.15

Lipidor AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.78 Mil.

Lipidor AB (OSTO:LIPI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Lipidor AB's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.474	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Lipidor AB's accounts receivable are only considered to be worth 75% of book value:

Lipidor AB's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	22.753	-	7.976	+	0.75 * 0.474	+	0.5 * 0
=	15.13

Lipidor AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Lipidor AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipidor AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lipidor AB (OSTO:LIPI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

L7R:Germany

Address

c/o Ekonomistubben AB, Box 55931, Stockholm, SWE, 102 16

Website

https://www.lipidor.se

Lipidor AB is a pharmaceutical development company with a pipeline of drug development projects in the preclinical and clinical phases. The company develops drugs for the treatment of skin diseases such as psoriasis, bacterial skin infections, and atopic dermatitis.

Lipidor AB Headlines

No Headlines